Trials / Completed
CompletedNCT00407745
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | Placebo |
| DRUG | pregabalin | Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day) |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2006-12-05
- Last updated
- 2021-01-25
- Results posted
- 2011-12-08
Locations
67 sites across 10 countries: United States, Chile, China, Colombia, Czechia, Hong Kong, India, Japan, Philippines, Russia
Source: ClinicalTrials.gov record NCT00407745. Inclusion in this directory is not an endorsement.